Monthly Archives: June 2022

Hormone Replacement Therapy Market to 2022 Updated with Impact of COVID-19 is latest research study released by Adroit Market Research evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Hormone Replacement Therapy Market to 2030 Updated with Impact of COVID-19 Market.

Get Free Sample Report + All Related Table and Graphs @ https://www.thebrainyinsights.com/enquiry/sample-request/12564

Hormone Replacement Therapy Market to 2030 Updated with Impact of COVID-19 Industry Overview:

The Brainy Insights Hormone Replacement Therapy Market to 2030 Updated with Impact of COVID-19 provides a comprehensive coverage on Hormone Replacement Therapy industry. It provides historical and forecast data on the countrys coal production, consumption, and imports. The production section provides an extensive analysis over the trend of production, impact of the COVID-19 and information on production by company, by type, by grade and by state. The report also provides detail for reserves by state and country. The trade section briefs about major partners involve in this market. An extensive demand drivers section provides information on factors that are affecting the countrys coal demand such as domestic demand from power and steel industry. It further includes profiles of producers, information on the major active, planned and exploration projects.

Important years considered in the study are: Historical year 2015-2022; Base year 2022; Forecast period** 2022 to 2030 [** unless otherwise stated]

Market segments and sub-segments:

Type such as

Application such as

Hormone Replacement Therapy Market Scope:

The report contains an overview of Hormone Replacement Therapy industry and the impact of COVID-19 on the countrys Hormone Replacement Therapy market. It also includes key driving factors that affects global demand such as demand from the application industry.

It provides detailed information on reserves by country, production, production by state, company, type and grade. Along with this, major operating, exploration and development projects, competitive landscape and major importers are also included in the report.

Read Detailed Index of full Research Study at @ https://www.thebrainyinsights.com/report/hormone-replacement-therapy-market-12564

Reasons to Buy:

Key Answers Captured in Study are

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand].

Enquire for customization in Report @ https://www.thebrainyinsights.com/enquiry/request-customization/12564

About The Brainy Insights:

The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients objectives of high-quality output within a short span of time. We provide both customized (clients specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients requirement whether they are looking to expand or planning to launch a new product in the global market.

Contact Us

Avinash D

Head of Business Development

Phone: +1-315-215-1633

Email: [emailprotected]

Web: http://www.thebrainyinsights.com

Read the original post:
Top 10 Hormone Replacement Therapy Industry to Look Out for in 2022 by Abbott Laboratories, Novartis, Pfizer, Inc., Mylan Laboratories - Digital...

Top-rated Caribbean Med School offers the latest research, insights, and resources for med students, healthcare providers, and allies

NEW YORK, June 21, 2022 /PRNewswire-PRWeb/ -- The University of Medicine and Health Sciences, (UMHS), a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada, today announced that it will host a live stream event, "LGBTQ+ Medicine & Theory: Providing Compassionate Care," on Wednesday, June 22 at 7 pm EDT. The discussion will be led by UMHS alumnus Soren Estvold, MD, MPH, a family medicine physician who specializes in treating LGBTQ+ patients at Augusta University Medical Center in Georgia and a volunteer physician at the Equality Clinic in Augusta, Georgia, a primary care clinic serving mostly transgender patients needing Hormone Replacement Therapy. The event will address key considerations for working with LGBTQ+ patients, describe how to provide compassionate care, offer practical advice for medical professionals and allies, and share resources for patients and providers. Following the presentation, current UMHS student Nisha Shetty will moderate a live Q & A session from the campus on St. Kitts. The event will be live-streamed on the UMHS YouTube channel as well as on the UMHS Facebook and LinkedIn pages. The presentation will also be recorded for future viewing.

"We are excited to welcome Dr. Estvold back for a presentation focused on the unique healthcare needs of the LGBTQ+ population at a time when this community is facing renewed attacks and barriers to receiving medical care," said Warren Ross, president of UMHS. "We're proud of Dr. Estvold's accomplishments in LGBTQ+ medicine, and are honored that he has once again agreed to share his insights with our students and offer specific guidance to deliver better health outcomes for LGBTQ+ patients."

Story continues

During the "LGBTQ+ Medicine & Theory" event, Dr. Estvold will define "full-spectrum medicine" and highlight the unique healthcare considerations of each subgroup within the community. He will also address the gender minority stress framework and how that impacts LGBTQ+ patients. Additionally, Dr. Estvold will offer insights on how to create an LGBTQ+-friendly practice and share advice for students interested in pursuing a specialty in LGBTQ+ medicine.

The discussion is the latest in a series of live stream events featuring UMHS faculty and alumni sharing their expertise on topics targeted toward current and prospective medical students and healthcare professionals. Past events include:

"Pathways to Practicing Medicine in Canada: UMHS Alumni Share Their Experiences"

"UMHS Women in Medicine: A Conversation About the First Year of Residency,"

"Cardiology: A Discussion About Cardiac Care & Careers in Cardiology,"

"Non-Traditional Medical Students - Medical School Admissions and Residency Advisors Reveal All!",

"Black Women in Medicine: A Conversation About the Black Experience",

"Ask a Microbiologist,"

"Suicide Prevention and the State of Psychiatry." and

"LGBTQ+ Medicine and Theory."

Links to view all past discussions may be found by visiting this link.

To join "LGBTQ+ Medicine & Theory: Providing Compassionate Care," on Wednesday, June 22, at 7 pm EDT visit the UMHS live events and meetings page.

About UMHS The University of Medicine and Health Sciences (UMHS), is a small, mission-driven medical school with a commitment to student support and a legacy of successful residency placements in the United States and Canada. UMHS was founded in 2007 by medical education pioneers Warren and Robert Ross to deliver a highly personalized school experience. Graduates of UMHS earn a Doctor of Medicine degree (MD) and qualify to practice medicine throughout the United States and Canada. Students begin their Basic Science studies in St. Kitts, West Indies, and complete their clinical training in the United States. With an unprecedented 96% student retention rate, the vast majority of students that begin their medical studies at UMHS go on to obtain residencies. For more information, visit https://www.umhs-sk.org/.

Media Contact

Megan Leer, UMHS, 619-708-9500, meganleerpr@gmail.com

Twitter

SOURCE University of Medicine and Health Sciences

Go here to read the rest:
University of Medicine and Health Sciences to Host "LGBTQ+ Medicine & Theory: Providing Compassionate Care" - Yahoo Finance

Anybody can breathe therefore anyone can practice yoga.T.K.V. Desikachar, yoga guru

Yoga is thousands of year-old discipline to engender mind-body harmony. Most of its development was between 500 BCE and 800 CE. From the 1970s, yoga spread worldwide and has become part of urban culture. The three main practices of Yoga are asana (posture), pranayama (breath control) and dhyana (meditation). Modern Yoga, or yoga in the modern age, is a combination of asanas and gymnastics.

Yoga was a spiritual practice. But in recent times it has emerged as a way to attain health which is defined by the World Health Organisation as complete physical, mental, and social well-being and not merely the absence of disease or infirmity.

Health benefits of yoga

Scientific evidence shows that therapeutic yoga has many health benefits. Numerous studies and anecdotal evidence also confirm health benefits of yoga.

Yoga can benefit health in thirty-eight ways. It can relieve back pain, improve heart health, improve strength, coordination, balance and flexibility, reduce inflammation, help in osteopenia, in oncology, and in recovery from surgery, help reduce anxiety and stress, ease arthritis symptoms, help sleep better, give more energy and brighter moods. Yoga may also boost immunity, improve bone health, improve brain functioning, and self-esteem.

Yoga and womens health

Yoga is especially beneficial in certain medical conditions typical to women. Six of these conditions are menopause, endometriosis, polycystic ovary syndrome (PCOS), uterine fibroids, premenstrual syndrome (PMS) and pregnancy.

Yoga and menopause

Women stop mensurating at a certain age. This condition is menopause. When a woman has not mensurated for twelve consecutive months, she has reached menopause. Natural menopause occurs in 40s or 50s. Premature menopause may occur before the age of 40 if ovaries are damaged, or are surgically removed, or because of medical treatment. After menopause, a woman cannot conceive.

At menopause, ovaries stop producing most of the female hormone estrogen. Low estrogen levels cause thirty-four symptoms. These can be severe (in 20% women), mild (60%) or no symptoms (20%). The symptoms may start during perimenopause, a period of 8-10 years before menopause. After menopause, during the post menopause period, symptoms ease for most women. But for some the symptoms may continue for ten years or longer.

The symptoms during perimenopause are: Heavier or lighter than usual periods Irregular or skipped periods Aggravated premenstrual syndrome (PMS) Breast tenderness.

Main symptoms of menopause are: Frequent urination Night sweats and/or cold flashes Hot flashes Insomnia and sleep disorders Dry vagina, discomfort during sex Dry mouth, eyes, and skin Mild depression, irritation, mood swings

A few women may also have: Joint and muscle aches and pains Hair loss or thinning Racing heart Headaches Weight gain Changes in libido (sex drive) Difficulty concentrating, memory lapses Higher risk of cardiovascular disease (CVD)

Therapy for menopause symptoms

Hormone Replacement Therapy (HRT), giving estrogen, is the most effective therapy for menopause symptoms. But HRT has many side effects. It also increases the risk of blood clots, certain types of cancer (breast cancer), cardiovascular disease, and strokes. HRT is therefore given only if essential, in smallest doses and for shortest time.

Yogic breathing techniques help women reduce hot flashes and night sweats. And yoga may alleviate insomnia and sleep disorders, depression, irritation, and mood swings, reduce joint and muscle aches and pains, reduce symptoms of severe PMS, reduce risk of CVD, and improve concentration and memory.

Today women in India live forty to fifty percent of their life in peri and post menopause phase. Yoga can help them cope with the symptoms of menopause.

Yoga and polycystic ovary syndrome (PCOS)

PCOS affects women of reproductive age. It increases the risk of infertility, endometrial and breast cancer, obesity, high blood pressure, heart problems, and diabetes. The exact cause of PCOS is unknown. But production of excess male hormone androgen and insulin, and certain genes are contributing factors. Treatment for PCOS is weight loss, healthy lifestyle, and some medications.

Yoga reduces testosterone levels, helps weight loss, stimulates reproductive organs, and improves emotional health, and thus limits the complications of PCOS.

Yoga and endometriosis

Endometriosis is caused by abnormal growth of the inner tissue of the uterus. It can cause infertility and chronic pelvic pain (CPP). It has no cure except removal of uterus. Surgical removal of tissues gives only temporary relief. Yoga reduces CPP but does not improve fertility.

Yoga and uterine fibroids and polyps

Uterine fibroids are benign tumors in the female reproductive tract. These are fed by hormones and blood, but the precise cause of their occurrence is unknown.

Yoga does not help shrink fibroids. But doing yoga during menstruation may increase blood flow into uterus and dilate uterine blood vessels. This may cause heavy bleeding and accelerate fibroid growth. Therefore, yoga should not be done during the first three days of period, or if the blood flow is heavy.

Yoga and premenstrual syndrome (PMS)

Premenstrual syndrome (PMS) occurs during late luteal phase of menstrual cycle and is relieved after the onset of menstruation. Main symptoms of PMS are mood swings, tender breasts, food cravings, fatigue, irritability, and depression. Three out of four women experience some symptom of PMS. Yoga, can reduce, or relieve, PMS distress

Yoga and pregnancy

Prenatal yoga reduces stress and anxiety, improves sleep, decrease lower back pain, nausea, headaches, and shortness of breath, and increases the strength, flexibility and endurance of muscles needed for childbirth. Yoga also causes increase in babys birth weight, decrease in preterm labor, and decrease in intrauterine growth restriction (IUGR). Hatha yoga and restorative yoga are also viable choice for pregnant women.

But talk to your doctor and to yoga instructor before starting yoga during pregnancy.

Conclusion

Yoga is cost-free and non-invasive. People of all ages benefit from yoga. It is good for womens health and well-being and is beneficial in certain medical conditions typical to women. For best results, integrate yoga with healthy lifestyle, healthy diet, exercise, therapeutic massage, and other stress-reducing measures.

Views expressed above are the author's own.

END OF ARTICLE

Read more:
International Yoga Day: Womens health & yoga - Times of India

STELLAR-303 is the first phase 3 pivotal trial evaluating XL092, a next-generation oral tyrosine kinase inhibitor

ALAMEDA, Calif., June 21, 2022--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-303, a phase 3 pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy. XL092 is a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced tumor types.

"There is a significant need for new treatment options for the majority of metastatic CRC patients, who do not have microsatellite instability-high or mismatch-repair deficient disease and whose tumors do not respond to immunotherapy alone," said Vicki L. Goodman, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. "Following recent promising data evaluating cabozantinib in combination with immunotherapies in colorectal cancer, we are thrilled to initiate our first phase 3 pivotal trial for XL092, our next-generation tyrosine kinase inhibitor. We look forward to learning more about how XL092 in combination with atezolizumab may benefit patients with metastatic colorectal cancer."

STELLAR-303 is a global, multicenter, randomized phase 3 open-label study that will enroll approximately 600 patients with documented RAS status. Patients will be randomized 1:1 to receive either XL092 in combination with atezolizumab or regorafenib. The primary objective of the study is to evaluate the efficacy of the combination in patients with RAS wild-type disease; exploratory endpoints include examining efficacy in those with RAS-mutated disease. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, objective response rate and duration of response per Response Evaluation Criteria in Solid Tumors version 1.1 as assessed by the investigator.

Previously announced results from two studies of cabozantinib in combination with immunotherapies for the treatment of advanced CRC supported Exelixis decision to pursue clinical development of XL092 in this setting. The trial is sponsored by Exelixis, and Roche is supplying atezolizumab.

About XL092

XL092 is a next-generation oral TKI that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. In designing XL092, Exelixis sought to build upon its extensive experience with and the target profile of cabozantinib, the companys flagship medicine, while improving key characteristics, including pharmacokinetic half-life. XL092 is currently being developed for the treatment of advanced solid tumors, including genitourinary cancers, as a monotherapy and in combination with immune checkpoint inhibitors. XL092 is the first internally discovered Exelixis compound to enter the clinic following the companys reinitiation of drug-discovery activities.

About Colorectal Cancer

Colorectal cancer is the third most common cancer and the third-leading cause of cancer-related deaths in the U.S. According to the American Cancer Society, about 150,000 new cases will be diagnosed and 53,000 people will die from the disease in 2022.1 Colorectal cancer is most frequently diagnosed among people aged 65-74 and is more common in men and those of African American descent. Nearly a quarter of colorectal cancer cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 15%.2 It has been estimated that approximately 40% of metastatic colorectal cancer cases exhibit a RAS mutation.3

About CABOMETYX (cabozantinib)

In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced renal cell carcinoma (RCC); for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for patients with advanced RCC as a first-line treatment in combination with nivolumab; and for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible. CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide. In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan. In 2017, Exelixis granted exclusive rights to Takeda for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

CABOMETYX is not indicated as a treatment for metastatic colorectal cancer CRC that is not microsatellite instability-high or mismatch repair-deficient.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage: Severe and fatal hemorrhages occurred with CABOMETYX. The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies. Discontinue CABOMETYX for Grade 3 or 4 hemorrhage and prior to surgery as recommended. Do not administer CABOMETYX to patients who have a recent history of hemorrhage, including hemoptysis, hematemesis, or melena.

Perforations and Fistulas: Fistulas, including fatal cases, occurred in 1% of CABOMETYX patients. Gastrointestinal (GI) perforations, including fatal cases, occurred in 1% of CABOMETYX patients. Monitor patients for signs and symptoms of fistulas and perforations, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a Grade 4 fistula or a GI perforation.

Thrombotic Events: CABOMETYX increased the risk of thrombotic events. Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients. Fatal thrombotic events occurred in CABOMETYX patients. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.

Hypertension and Hypertensive Crisis: CABOMETYX can cause hypertension, including hypertensive crisis. Hypertension was reported in 37% (16% Grade 3 and <1% Grade 4) of CABOMETYX patients. Do not initiate CABOMETYX in patients with uncontrolled hypertension. Monitor blood pressure regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume at a reduced dose. Permanently discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy or for hypertensive crisis.

Diarrhea: Diarrhea occurred in 62% of CABOMETYX patients. Grade 3 diarrhea occurred in 10% of CABOMETYX patients. Monitor and manage patients using antidiarrheals as indicated. Withhold CABOMETYX until improvement to Grade 1, resume at a reduced dose.

Palmar-Plantar Erythrodysesthesia (PPE): PPE occurred in 45% of CABOMETYX patients. Grade 3 PPE occurred in 13% of CABOMETYX patients. Withhold CABOMETYX until improvement to Grade 1 and resume at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE.

Hepatotoxicity: CABOMETYX in combination with nivolumab can cause hepatic toxicity with higher frequencies of Grades 3 and 4 ALT and AST elevations compared to CABOMETYX alone. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes than when the drugs are administered as single agents. For elevated liver enzymes, interrupt CABOMETYX and nivolumab and consider administering corticosteroids.

With the combination of CABOMETYX and nivolumab, Grades 3 and 4 increased ALT or AST were seen in 11% of patients. ALT or AST >3 times ULN (Grade 2) was reported in 83 patients, of whom 23 (28%) received systemic corticosteroids; ALT or AST resolved to Grades 0-1 in 74 (89%). Among the 44 patients with Grade 2 increased ALT or AST who were rechallenged with either CABOMETYX (n=9) or nivolumab (n=11) as a single agent or with both (n=24), recurrence of Grade 2 increased ALT or AST was observed in 2 patients receiving CABOMETYX, 2 patients receiving nivolumab, and 7 patients receiving both CABOMETYX and nivolumab. Withhold and resume at a reduced dose based on severity.

Adrenal Insufficiency: CABOMETYX in combination with nivolumab can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold CABOMETYX and/or nivolumab and resume CABOMETYX at a reduced dose depending on severity.

Adrenal insufficiency occurred in 4.7% (15/320) of patients with RCC who received CABOMETYX with nivolumab, including Grade 3 (2.2%), and Grade 2 (1.9%) adverse reactions. Adrenal insufficiency led to permanent discontinuation of CABOMETYX and nivolumab in 0.9% and withholding of CABOMETYX and nivolumab in 2.8% of patients with RCC.

Approximately 80% (12/15) of patients with adrenal insufficiency received hormone replacement therapy, including systemic corticosteroids. Adrenal insufficiency resolved in 27% (n=4) of the 15 patients. Of the 9 patients in whom CABOMETYX with nivolumab was withheld for adrenal insufficiency, 6 reinstated treatment after symptom improvement; of these, all (n=6) received hormone replacement therapy and 2 had recurrence of adrenal insufficiency.

Proteinuria: Proteinuria was observed in 8% of CABOMETYX patients. Monitor urine protein regularly during CABOMETYX treatment. For Grade 2 or 3 proteinuria, withhold CABOMETYX until improvement to Grade 1 proteinuria, resume CABOMETYX at a reduced dose. Discontinue CABOMETYX in patients who develop nephrotic syndrome.

Osteonecrosis of the Jaw (ONJ): ONJ occurred in <1% of CABOMETYX patients. ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain, or slow healing of the mouth or jaw after dental surgery. Perform an oral examination prior to CABOMETYX initiation and periodically during treatment. Advise patients regarding good oral hygiene practices. Withhold CABOMETYX for at least 3 weeks prior to scheduled dental surgery or invasive dental procedures, if possible. Withhold CABOMETYX for development of ONJ until complete resolution, resume at a reduced dose.

Impaired Wound Healing: Wound complications occurred with CABOMETYX. Withhold CABOMETYX for at least 3 weeks prior to elective surgery. Do not administer CABOMETYX for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of CABOMETYX after resolution of wound healing complications has not been established.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic findings on MRI, can occur with CABOMETYX. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Thyroid Dysfunction: Thyroid dysfunction, primarily hypothyroidism, has been observed with CABOMETYX. Based on the safety population, thyroid dysfunction occurred in 19% of patients treated with CABOMETYX, including Grade 3 in 0.4% of patients.

Patients should be assessed for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitored for signs and symptoms of thyroid dysfunction during CABOMETYX treatment. Thyroid function testing and management of dysfunction should be performed as clinically indicated.

Hypocalcemia: CABOMETYX can cause hypocalcemia. Based on the safety population, hypocalcemia occurred in 13% of patients treated with CABOMETYX, including Grade 3 in 2% and Grade 4 in 1% of patients. Laboratory abnormality data were not collected in CABOSUN.

In COSMIC-311, hypocalcemia occurred in 36% of patients treated with CABOMETYX, including Grade 3 in 6% and Grade 4 in 3% of patients.

Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume at reduced dose upon recovery or permanently discontinue CABOMETYX depending on severity.

Embryo-Fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Verify the pregnancy status of females of reproductive potential prior to initiating CABOMETYX and advise them to use effective contraception during treatment and for 4 months after the last dose.

ADVERSE REACTIONS

The most common (20%) adverse reactions are:

CABOMETYX as a single agent: diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, constipation.

CABOMETYX in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.

DRUG INTERACTIONS

Strong CYP3A4 Inhibitors: If coadministration with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage. Avoid grapefruit or grapefruit juice.

Strong CYP3A4 Inducers: If coadministration with strong CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage. Avoid St. Johns wort.

USE IN SPECIFIC POPULATIONS

Lactation: Advise women not to breastfeed during CABOMETYX treatment and for 4 months after the final dose.

Hepatic Impairment: In patients with moderate hepatic impairment, reduce the CABOMETYX dosage. Avoid CABOMETYX in patients with severe hepatic impairment.

Please see accompanying full Prescribing Information https://www.cabometyx.com/downloads/CABOMETYXUSPI.pdf.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.FDA.gov/medwatch or call 1-800-FDA-1088.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), COTELLIC (cobimetinib) and MINNEBRO (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poors (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit http://www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Forward-looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to: the clinical and therapeutic potential of XL092 in combination with atezolizumab as a treatment for patients with metastatic colorectal cancer; and Exelixis plans to reinvest in its business to maximize the potential of the companys pipeline, including through targeted business development activities and internal drug discovery. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the potential failure of the combination of XL092 and atezolizumab to demonstrate safety and/or efficacy in STELLAR-303; uncertainties inherent in the product development process; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis and Roches continuing compliance with applicable legal and regulatory requirements; the continuing COVID-19 pandemic and other global events and their impact on Exelixis research and development operations, including Exelixis ability to initiate new clinical trials and clinical trial sites, enroll clinical trial patients, conduct trials per protocol, and conduct drug research and discovery operations and related activities; the costs of conducting clinical trials; Exelixis dependence on third-party vendors for the development, manufacture and supply of XL092; Exelixis ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs discussed under the caption "Risk Factors" in Exelixis Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2022, and in Exelixis future filings with the SEC. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.COTELLIC is a registered trademark of Genentech, Inc.MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

_______________________1 Cancer Facts and Figures 2022. American Cancer Society website. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf. Accessed June 2022.2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: https://seer.cancer.gov/statfacts/html/colorect.html. Accessed June 2022.3 RAS in Colorectal Cancer: ESMO Biomarker Factsheet. OncologyPRO website. Available at https://oncologypro.esmo.org/education-library/factsheets-on-biomarkers/ras-in-colorectal-cancer. Accessed June 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005441/en/

Contacts

Investors: Susan Hubbard EVP, Public Affairs andInvestor Relations Exelixis, Inc. (650) 837-8194 shubbard@exelixis.com

Media: Lindsay Treadway Executive Director, Public Affairsand Advocacy Relations Exelixis, Inc. (650) 837-7522 ltreadway@exelixis.com

Original post:
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer - Yahoo Finance

The market received the proverbial haymaker from the Federal Reserve last week, when the central bank raised interest rates by 75 basis points, the largest increase since November of 1994. To add insult to injury, unless the Fed governors and Chair Jay Powell see at least some decline in the staggering inflation, you can count on another 75-basis-point increase in July.

With the market getting absolutely torched last week, the venerable Dow Jones industrials dipped below the 30,000 level, and both the S&P 500 and the Nasdaq are in bear market territory. Many investors are worried, and with good reason. After years of loose money policy, the party is over, and it is time to move assets to safe, dividend-paying companies to ride out the storm. With the potential for a recession increasing, the time to reallocate is now.Often when income investors look for companies paying big dividends, they are drawn to the Dividend Aristocrats, and with good reason. The 66 companies that made the cut for the 2022 S&P 500 Dividend Aristocrats list have increased dividends (not just remained the same) for 25 years straight. But the requirements go even further. The following attributes are also mandatory for membership on the vaunted list:

With the potential for massive downside still looming, and interest rates definitely still going higher, we thought it would be a good idea to look for companies on the Dividend Aristocrats list that are in defensive sectors and look poised to do well the rest of 2022.

Seven stocks hit our screens, all of which are Buy rated at top Wall Street firms. It is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.

This is a top pharmaceutical and med-tech stock with very solid growth potential. Abbott Laboratories (NYSE: ABT) manufactures and sells health care products worldwide.

Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Mnires disease and vestibular vertigo; pain, fever and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.

The LabsDiagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnose cancer, cardiac, drugs of abuse, fertility, infectious diseases and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic-based tests; informatics and automation solutions; and a suite of informatics tools and professional services.

Abbott Laboratories stock investors receive a 1.83% dividend. Morgan Stanleys price target is $145, and the consensus target is $139.29. The shares closed most recently at $102.53.

See the rest here:
7 Strong Buy Dividend Aristocrats Are Safe-Haven Stocks to Own During a Recession - 24/7 Wall St.